Skip to main content

Find Clinical Trials

Home
Conditions
Blasts More Than 20 Percent of Peripheral Blood White Cells

Clinical trial condition

Blasts More Than 20 Percent of Peripheral Blood White Cells

Explore clinical trials studying Blasts More Than 20 Percent of Peripheral Blood White Cells. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Blasts More Than 20 Percent of Peripheral Blood White Cells trial results

Completed

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

NCT02257138

Conditions: Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Bone Marrow Diseases, +11 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details